ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AKBA Akebia Therapeutics Inc

1.975
-0.265 (-11.83%)
Last Updated: 11:50:38
Delayed by 15 minutes

Period:

Draw Mode:

Volume 41,040,495
Bid Price 1.97
Ask Price 1.98
News (1)
Day High 2.48

Low
0.4901

52 Week Range

High
2.48

Day Low 1.88
Company Name Stock Ticker Symbol Market Type
Akebia Therapeutics Inc AKBA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.265 -11.83% 1.975 11:50:38
Open Price Low Price High Price Close Price Prev Close
2.47 1.88 2.48 2.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
122,003 41,040,495 $ 2.12 $ 86,925,545 - 0.4901 - 2.48
Last Trade Time Type Quantity Stock Price Currency
11:50:41 1 $ 1.975 USD

Akebia Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
425.03M 209.37M - 292.6M -92.56M -0.44 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Akebia Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AKBA Message Board. Create One! See More Posts on AKBA Message Board See More Message Board Posts

Historical AKBA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.962.481.882.138,568,3690.0150.77%
1 Month1.582.481.341.855,302,0800.39525.00%
3 Months1.382.481.291.713,260,9430.59543.12%
6 Months1.182.480.78011.492,267,3250.79567.37%
1 Year0.64012.480.49011.351,997,4391.33208.55%
3 Years3.104.330.2411.353,673,001-1.13-36.29%
5 Years8.4613.780.2412.483,394,014-6.49-76.65%

Akebia Therapeutics Description

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Your Recent History

Delayed Upgrade Clock